Medicare Part D prescribing data offers insight

Medicare Part D prescribing data offers insight

Publicly available Medicare prescription drug data gives doctors the ability to compare prescribing practices among peers and across professions, making for a vital practice management and advocacy tool.

Optometry ranks among the top 10 specialties with the highest number of Part D prescribers.

Initially released by the Centers for Medicare & Medicaid Services (CMS) earlier in 2015, the new Medicare Provider Utilization and Payment Data offers a privacy-protected database that lists providers and the drugs they prescribed in 2013 as part of the Medicare Part D prescription drug program. The listing includes total number of prescriptions by drug name and total drug cost in CMS' stated effort to promote better care and smarter spending in the federal program.

The dataset contains information from more than 1 million providers who collectively prescribed more than 3,000 distinct drug products, and about $103 billion in prescription drugs and supplies paid under the Part D program in 2013.

Optometry by the numbers
Optometry ranks among the top 10 specialties—No. 10—with the highest number of Part D prescribers, at 25,654. According to the dataset, optometry averages 4.8 unique drug products prescribed at an average total cost per provider of $17,501. That's in comparison to a group such as family practitioners, who prescribed the highest average of drug products, 75, at an average total cost per provider of $211,977.
These doctors of optometry account for a total drug cost of $339.4 million with the top 5 drug costs, including:

  1. Ciclosporin (Restasis): $103.5 million (31 percent)
  2. Travoprost (Travatan Z): $50.3 million (15 percent)
  3. Bimatoprost (Lumigan): $47.6 million (14 percent)
  4. Latanoprost: $18.4 million (5 percent)
  5. Olopatadine HCL (Pataday): $17 million (5 percent

Ophthalmology accounted for a total drug cost of $1.8 billion with the top 5 drug costs, including:

  1. Ciclosporin (Restasis): $267.2 million (15 percent)
  2. Bimatoprost (Lumigan): $243.6 million (13 percent)
  3. Travoprost (Travatan Z): $183.4 million (10 percent)
  4. Brimonidine/timolol (Combigan): $103.9 million (6 percent)
  5. Brimonidine tartrate (Alphagan P): $103.8 million (6 percent)

Click here to access CMS' Medicare Provider Utilization and Payment Data lookup tool to search by provider and view the full dataset. Read more about optometry's prescribing habits in the June 2015 edition of AOA Focus.

November 11, 2015

comments powered by Disqus